TD Cowen lowered the firm’s price target on Surgery Partners (SGRY) to $20 from $28 and keeps a Buy rating on the shares. The firm updated it model following Q4 results where EBITDA was below consensus due to negative insurance mix shift and market-specific issues at 3 surgical hospitals.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $17 from $19 at Mizuho
- Surgery Partners price target lowered to $21 from $29 at UBS
- Surgery Partners price target lowered to $24 from $30 at Benchmark
- Surgery Partners price target lowered to $20 from $31 at RBC Capital
- Surgery Partners Earnings Call Balances Growth And Strain